Scheduling conflicts delay the FDA's Orthopaedic & Rehabilitation Devices Panel, during which the agency was planning to discuss a possible reclassification of shortwave diathermy devices.
The FDA's Orthopaedic & Rehabilitation Devices Panel postponed today's meeting over scheduling conflicts that meant key players couldn't attend.
The meeting was convened to discuss a possible reclassification of shortwave diathermy devices, which are used to therapeutically heat tissue with an electric current with applications in joint inflammation treatments and physiotherapy.
The FDA is considering pushing shortwave diathermy devices to Class III status, to require premarket approval.
The federal watchdog agency hasn't announced a new meeting date, but said it will issue a notice in the Federal Register when a new appointment as been made.
The FDA plans a public workshop on robotically-assisted surgical devices to solicit feedback on how...
Regdy blog's Andrew Ahn discusses the advantages of getting your device approved by FDA.
EndoChoice says it raised $57 million from a syndicate of prior and new backers it plans to use boost...
Europe's top court rules that Boston Scientific must cover the cost of replacing defective pacemakers...
Medtronic invests in anti-leg-cramp drug maker Flex Pharma's initial public offering.